US Rheumatoid Arthritis Treatment Market Value to Reach $9.3 Billion
The US treatment market for Rheumatoid Arthritis (RA) is set to increase in value from $6.4 billion in 2013 to $9.3 billion by 2020, representing a Compound Annual Growth Rate (CAGR) of 5.5%, says business intelligence provider GBI Research.
The company’s report, Rheumatoid Arthritis Market to 2020 – A Crowded Market Characterized by Modest Growth, states that this growth will be driven partly by the US’ increasing prevalent population, which is forecast to hit 1.68 million by 2020. Consequently, the country will remain the largest RA therapeutics player of the eight major pharmaceutical markets (the US, UK, Canada, France, Germany, Spain, Italy and Japan) over the forecast period.
Furthermore, Yasser Mushtaq, Senior Analyst for GBI Research, says the entry of premium-priced, disease-modifying therapies into the US’ RA treatment arena, along with new biosimilar products, will also be a contributing factor to its expansion.
However, as Mushtaq explains “While the patent expiration of blockbuster drugs as early as this year is expected to cause strong biosimilar uptake in the EU, thereby reducing the Annual Cost of Therapy (ACoT) in this region, these products may not measurably affect the pricing of currently marketed RA treatments in the US.
“Despite the fact that biosimilars are likely to be priced at a discount to their reference drug, the lack of regulatory guidelines for their approvals in the US may deter drug manufactures from seeking marketing approval for these products.”
The analyst adds that drug developers may be further discouraged by state legislation preventing clinicians from taking up biosimilar versions of their reference drugs. This will result in a stable ACoT for RA treatments in the US over the forecast period.
Mushtaq concludes “The US had the highest ACoT of the eight major markets in 2013, with $5,983, reflecting the country’s higher drug costs in comparison with Canada and the EU. This figure is expected to grow at a CAGR of 3.2% to reach $7,435 by 2020.”
This report provides forecasts for the global rheumatoid arthritis treatment market, including epidemiology, treatment usage pattern, pricing and market size for the 2013–2020 period, for which data are presented at country level with further analysis of key market drivers and barriers. It was built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis conducted by GBI Research’s team of industry experts.
GBI Research is a market-leading provider of business intelligence reports, offering actionable data and forecasts based on the insights of key industry leaders to ensure you stay up-to-date with the latest emerging trends in your markets. For more information, please contact the Press Office on +44 (0)1204 543 537 or at pr@gbiresearch.com . Follow us online for the latest industry updates Facebook | LinkedIn | Twitter
Total Page Views: 4967
